Medication info
Cabergactin Tablet 1mg (Cabergoline)

Cabergactin Tablet 1mg (Cabergoline)

Prescription medicationTabletOral
Ingredient · strength
Cabergoline›1mg / 1 tablet
Manufacturer / importer
Dong-gu Bio Pharmaceutical Co., Ltd.
Appearance
White rectangular tablet
Packaging
24 tablets/bottle
Approval status
Active

MFDS item code 201500628 · Approved 2015.02.05 · Insurance code 657306590

Summary

Main use
Treatment of hyperprolactinemia; prevention and suppression of lactation
Who takes it
Adults
Adult dose
This medicine is for oral administration. Dopamine agonists such as this medicine are better tolerated when taken with food; therefore, take this medicine immediately after a meal for all indications. 1. Prevention and suppression of lactation 1) Suppression of lactation: Take 1mg of cabergoline as a single dose on the first day after delivery. 2) Suppression of established lactation: Take 0.25mg of cabergoline every 12 hours for 2 days (total 1mg). 2. Treatment of hyperprolactinemia: The recommended initial dose is 0.5mg of cabergoline once or twice weekly (e.g., 1/2 tablet on Monday and Thursday). Gradually increase the dose by 0.5mg of cabergoline per week, preferably at monthly intervals, until the optimal treatment response is achieved. The usual therapeutic dose is 1mg of cabergoline per week, with a range of 0.5mg ~ 2mg per week. The maximum dose should not exceed 4.5mg of cabergoline per week or 3mg daily. Adjust the dosing frequency to once weekly or twice or more weekly according to the patient's compliance. Tolerability of doses of 1mg or more of cabergoline taken once weekly has been evaluated in only a small number of patients; therefore, if taking 1mg or more of cabergoline per week, divided dosing is recommended. During dose escalation, evaluate the patient to determine the minimum dose that produces a treatment response. Monitor serum prolactin levels monthly. Once an effective therapeutic dose is reached, serum prolactin concentrations usually return to normal within 2~4 weeks. Symptoms of hyperprolactinemia may recur after this medicine is discontinued. In some patients, prolactin levels have been observed to remain low for several months. In follow-up of a group of women who discontinued this medicine, 23 of 29 continued to have ovulatory cycles for more than 6 months after discontinuation.

Ingredients

Manufacturer
Dong-gu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hyperprolactinemia; prevention and suppression of lactation

  • Milk secretion
  • inability to breastfeed
  • stillbirth
  • miscarriage
  • amenorrhea
  • oligoamenorrhea
  • anovulation
  • galactorrhea
  • hyperprolactinemia
  • prolactin-secreting pituitary adenoma
  • Sheehan’s syndrome
View approved original text

This medication is used to prevent or inhibit milk secretion after childbirth, particularly when the mother does not wish to breastfeed or when breastfeeding is difficult for medical reasons, and to prevent milk secretion following stillbirth or miscarriage. In addition, this medication is effective in treating symptoms such as amenorrhea, oligoamenorrhea, anovulation, galactorrhea caused by hyperprolactinemia. It is also used in patients with causes such as prolactin-secreting pituitary adenomas or idiopathic hyperprolactinemia, and Sheehan’s syndrome, to improve related symptoms. This medication is used for suppression of milk secretion after childbirth and treatment of hyperprolactinemia.

How to take

Adult dose

This medicine is for oral administration. Dopamine agonists such as this medicine are better tolerated when taken with food; therefore, take this medicine immediately after a meal for all indications. 1. Prevention and suppression of lactation 1) Suppression of lactation: Take 1mg of cabergoline as a single dose on the first day after delivery. 2) Suppression of established lactation: Take 0.25mg of cabergoline every 12 hours for 2 days (total 1mg). 2. Treatment of hyperprolactinemia: The recommended initial dose is 0.5mg of cabergoline once or twice weekly (e.g., 1/2 tablet on Monday and Thursday). Gradually increase the dose by 0.5mg of cabergoline per week, preferably at monthly intervals, until the optimal treatment response is achieved. The usual therapeutic dose is 1mg of cabergoline per week, with a range of 0.5mg ~ 2mg per week. The maximum dose should not exceed 4.5mg of cabergoline per week or 3mg daily. Adjust the dosing frequency to once weekly or twice or more weekly according to the patient's compliance. Tolerability of doses of 1mg or more of cabergoline taken once weekly has been evaluated in only a small number of patients; therefore, if taking 1mg or more of cabergoline per week, divided dosing is recommended. During dose escalation, evaluate the patient to determine the minimum dose that produces a treatment response. Monitor serum prolactin levels monthly. Once an effective therapeutic dose is reached, serum prolactin concentrations usually return to normal within 2~4 weeks. Symptoms of hyperprolactinemia may recur after this medicine is discontinued. In some patients, prolactin levels have been observed to remain low for several months. In follow-up of a group of women who discontinued this medicine, 23 of 29 continued to have ovulatory cycles for more than 6 months after discontinuation.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to this medication or its components or have fibrosis or dysfunction in the lungs, heart, or liver should not take it. Caution is also required for patients with preeclampsia or those taking psychiatric medications. Patients with liver or kidney function issues, or severe cardiovascular diseases should use this medication cautiously. Especially, patients taking antihypertensive medications may experience symptoms of hypotension, so they should be careful. Women who are pregnant or may become pregnant should consult a doctor before taking this medication and should immediately discontinue it if pregnancy is confirmed during treatment. Additionally, this medication contains lactose, so patients with lactose intolerance should avoid taking it. Side effects such as dizziness, headache, abdominal pain, dyspepsia, fatigue may occur when taking this medication, and rarely serious problems such as valvular heart disease or pulmonary fibrosis may occur. If such symptoms appear, inform healthcare professionals immediately. This medication may induce narcolepsy or sudden sleep attacks, so caution is required when driving or operating machinery during treatment. Moreover, symptoms such as impulse control disorders may occur, necessitating regular monitoring. Long-term use should be accompanied by regular examinations, such as echocardiograms and pulmonary function tests, to check heart and lung health. The dosage of this medication should be kept to a minimum and taken according to the physician's instructions. Caution is required regarding interactions with other medications, particularly avoiding concomitant use with dopamine antagonists or certain antibiotics. Safety in children and the elderly has not been fully established, so special caution is necessary when using this medication. In cases of overdose, symptoms such as vomiting, hypotension, and confusion may occur, necessitating immediate medical attention. This medication should be kept out of the reach of children and should not be transferred to other containers.

Side effects

Postural hypotension, vasospasm of the fingers, syncope, leg cramps, muscle weakness, hair loss, pruritus, rash, allergic skin reactions, decreased hemoglobin levels, depression, sleep disorders, aggression, hypersexuality, pathological gambling, increased libido, dizziness, lightheadedness, headache, altered perception, somnolence, facial flushing, abdominal pain, dyspepsia, gastritis, nausea, constipation, vomiting, breast pain, asthenia, fatigue, hypersomnia, valvular heart disease, pericarditis, pericardial effusion, palpitations, nosebleed, asymptomatic hypotension symptoms, pleural effusion, pulmonary fibrosis, upper abdominal pain, lethargy, temporary scotoma, hypersensitivity, delusions, edema, increased serum creatine phosphokinase levels, nausea, discomfort in the stomach, confusion, psychosis, hallucinations

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in special containers that block light. Moreover, it is important to store it at room temperature, i.e., below 25 degrees Celsius, to maintain its effectiveness.

Appearance and packaging

Appearance

White rectangular tablet

Package unit

24 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.